Business
Appointment
Appointment.
About this update from Aura Renewable Acquisitions Plc
[{"type":"text","content":"\n Ardana PLC\n17 March 2006\n\n Ardana appoints Klaus Falk as VP Sales & Marketing\n\n\nEdinburgh, UK, 17 March 2006; Ardana plc (LSE:ARA) the emerging pharmaceutical\ncompany focused on improving human reproductive health, announces the\nappointment of Klaus Falk as Vice President, Sales & Marketing.\n\nMr Falk, aged 46, has over 20 years of experience in the pharmaceutical\nindustry, gained at Merck KGaA in a number of posts including 8 years as a\nGeneral Manager in Central and South America. Whilst based in Germany, he gained\nexperience in a range of strategic projects including M&A and the company's IPO\nin 1995. As Vice President, Europe, he was responsible for Sales & Marketing and\nhis achievements included the successful launch of the oncology franchise's\nfirst product, Erbitux, in 2003.\n\nCommenting, Dr Maureen Lindsay, Ardana's CEO, said, 'Klaus's deep and broad\nexperience over the last 20 years will bring significant benefits to Ardana as\nwe build further on our sales and marketing capabilities in the UK and Europe.\nWith Striant on the market; a planned launch for Invicorp later this year, and\nvarious in-licensing opportunities, we are delighted that Klaus will be leading\nthese key activities'.\n\n\nFor more information contact:\n\nArdana Financial Dynamics\nMaureen Lindsay (corporate/financial media relations)\nTel: + 44 (0) 131 226 8550 Julia Phillips/John Gilbert\n Tel: +44 (0)20 7831 3113\n\n NB Public Relations\n trade/technical media relations)\n Nicki Brimicombe\n Tel: + 44 (0)1883 732353\n\n\nAbout Ardana\n\nArdana plc is a pharmaceutical company focused on the discovery, development and\nmarketing of innovative products to improve human reproductive health, a $23.8\nbillion market.\n\nSince its foundation, Ardana has maintained a broad and balanced portfolio to\nmanage risk and actively pursues product and technology in-licensing and\nout-licensing to maintain a robust pipeline.\n\nArdana's four lead products are summarised below:\n\n • Striant(TM) SR, a testosterone replacement therapy for which Ardana has\n marketing rights in Europe, has already been launched by Ardana through its\n own sales force in the UK as a treatment for men with confirmed hypogonadism\n • Teverelix LA, in development for three initial indications: prostate\n cancer and benign prostatic hyperplasia (both...